BICTEGRAVIR SODIUM, LENACAPAVIR SODIUM; LENACAPAVIR SODIUM | N221443 | GILEAD SCIENCES INC
| Patent # | Expiration | PED | Drug Substance | Drug Product | Use Code | Delist |
|---|---|---|---|---|---|---|
| 9216996Newly listed — daily FDA feed, not yet in monthly Orange Book edition | Dec 19, 2033 | — | Yes | Yes | — | — |
| 9708342Newly listed — daily FDA feed, not yet in monthly Orange Book edition | Jun 19, 2035 | — | Yes | Yes | — | — |
| 9732092Newly listed — daily FDA feed, not yet in monthly Orange Book edition | Dec 19, 2033 | — | Yes | Yes | — | — |
| 9951043Newly listed — daily FDA feed, not yet in monthly Orange Book edition | Feb 28, 2034 | — | Yes | Yes | — | |
| 10071985Newly listed — daily FDA feed, not yet in monthly Orange Book edition | Aug 17, 2037 | — | Yes | Yes | — | — |
| 10385067Newly listed — daily FDA feed, not yet in monthly Orange Book edition | Jun 19, 2035 | — | — | — | — | |
| 10654827Newly listed — daily FDA feed, not yet in monthly Orange Book edition | Aug 17, 2037 | — | — | — | — | |
| 11267799Newly listed — daily FDA feed, not yet in monthly Orange Book edition | Aug 16, 2038 | — | Yes | — | — | — |
| Code | Date | Status |
|---|---|---|
| NCENewly listed — daily FDA feed, not yet in monthly Orange Book edition | Dec 22, 2027 | Active |
| NPNewly listed — daily FDA feed, not yet in monthly Orange Book edition | Aug 27, 2029 | Active |
BIXLENVO SUNLENCA STARTER PACK (bictegravir sodium/lenacapavir sodium) acquired new product exclusivity expiring Aug 2029.
New: BIXLENVO SUNLENCA STARTER PACK (COPACKAGED) (BICTEGRAVIR SODIUM, LENACAPAVIR SODIUM; LENACAPAVIR SODIUM ) — exclusivity NP exp 08/27/2029
Gilead Sciences' bictegravir sodium/lenacapavir sodium copackaged product (BIXLENVO SUNLENCA STARTER PACK) gained new chemical entity exclusivity expiring Dec 2027.
New: BIXLENVO SUNLENCA STARTER PACK (COPACKAGED) (BICTEGRAVIR SODIUM, LENACAPAVIR SODIUM; LENACAPAVIR SODIUM ) — exclusivity NCE exp 12/22/2027